pennvax-g dna vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01260727)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pennvax-g dna vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03606213 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2018 | Inovio Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles, University of California, San Francisco |
| NCT01260727 | Phase 1 | Feb 1, 2010 | National Institute of Allergy and Infectious Diseases (NIAID), United States Army |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 1 | 2 | 2010 |
| Inovio Pharmaceuticals | For profit | 1 | 0 | 1 | 2018 |
| United States Army | Government | 1 | 0 | 1 | 2010 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2018 |
5 organizations
Page 1 / 1